Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15018458 | 0.78 | KCNJ1 (0.44) | KCNJ1NOTUM | |
| SCHEMBL16232248 | 0.68 | KCNJ1 (0.42) | KCNJ1NOTUM | |
| SCHEMBL19381056 | 0.65 | KCNJ1 (0.39) | KCNJ1NOTUM | |
| SCHEMBL15196768 | 0.65 | KCNJ1 (0.48) | KCNJ1 | |
| SCHEMBL16232247 | 0.64 | KCNJ1 (0.38) | KCNJ1 | |
| SCHEMBL18213684 | 0.63 | KCNJ1 (0.58) | KCNJ1NOTUM | |
| SCHEMBL20342517 | 0.62 | KCNJ1 (0.40) | KCNJ1NOTUM | |
| SCHEMBL16232245 | 0.62 | NOTUM (0.44) | KCNJ1NOTUM | |
| SCHEMBL15196742 | 0.62 | KCNJ1 (0.44) | KCNJ1NOTUM | |
| SCHEMBL18216589 | 0.59 | GPR119 (0.43) | KCNJ1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206199-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20140336177-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2014-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336177-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | KCNJ1 2/4885NOTUM 4002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.